Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma
Chronic Lymphocytic Leukemia
B Cell Malignancies
Non-Hodgkin's Lymphoma

Interventions

DRUG: ABBV-525

Sponsor

AbbVie